Welcome to Labtec

Labtec GmbH, an innovative and internationally oriented pharmaceutical company, is focussed on

research and development of drug delivery systems

• transdermal delivery systems
• buccal/gingival delivery systems
• fast dissolving oral dosage forms and
  
  

contract analytics according to international standards.

 

 

 

Labtec NEWS

 

Jul 09: Ondansetron Rapidfilm® Licensed to SciClone Pharmaceuticals for China

 

Jun 09: APR Enters into Licensing Deal with Abdi Ibrahim 
for Ondansetron Rapidfilm® in Turkey

Feb 09: Ondansetron RapidFilm™  submitted for approval

 

 

Nov 08: tesa AG Acquires Labtec GmbH

 

Aug 08: Ondansetron RapidFilm™ licensed to BioAlliance Pharma for Europe

 

Feb 08: APR Applied Pharma Research and Labtec announce the successful completion of the Pilot Bioequivalence study of their Donepezil RapidFilm™

 

Jan 08: APR Applied Pharma Research and Labtec announce the successful completion of the Pivotal Bioequivalence study for their proprietary Ondansetron RapidFilm™

 

 Nov 07: Inauguration of Labtec´s new company building by the mayor of Langenfeld

Apr 07: Labtec’s next generation pain patch successful in clinical studies

 Mar 07: Labtec and APR announce positive results for Ondansetron RapidFilm


 Sep 06: Fentanyl patch developed by Labtec GmbH first generic to be approved for marketing in Canada

 Jul 06: RapidFilm: Oral Thin Films (OTF) as an Innovative Drug Delivery System and Dosage Form

 Mar 06: Labtec and APR sign partnership agreement
for Oral Thin Films

 Jan 06: Fentanyl patch developed by Labtec GmbH approved for marketing in Germany

 Jan 06: LabiPatch: Labtec´s revolutionary novel approach to treatment of Herpes labialis